HCPCS code M1412 — Met nsclc w/ egfr alk oth ab. Status: Active. Effective Jan 1, 2025. Source: CMS HCPCS Level II.

M1412

Active

Met nsclc w/ egfr alk oth ab

Patients with metastatic nsclc with epidermal growth factor receptor (egfr) mutations, alk genomic tumor aberrations, or other targetable genomic abnormalities with approved first-line targeted therapy, such as nsclc with ros1 rearrangement, braf v600e mutation, ntrk 1/2/3 gene fusion, met ex14 skipping mutation, and ret rearrangement

Category: Medical Services
Section: M-codes: Medical Services
Effective: Jan 1, 2025
Code type: alphanumeric
OPPS Status: M — Items / services not billable to the fiscal intermediary or MAC

Change History

Quarterly changes published by CMS. Revisions may affect the code description, coverage, or rate — review each quarter's changes before submitting claims.

  • New Code 2025-Q1
    Met nsclc w/ egfr alk oth ab